Elizabeth J. Davis

Biochemistry, Genetics and Molecular BiologyMedicineChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile

0.140Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11523

Top 71%

0.140DataRank

Top 71%1 citations

Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah +15 more

Papers

Driven by 20 papers — median percentile 15. Top paper: “Atezolizumab for Advanced Alveolar Soft Part Sarcoma”.

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11503

N/A

0.542DataRank · unranked

36 citations

Jacob B. Allred, Scott M. Schuetze, Elizabeth J. Davis, Michael J. Wagner, Andrew Poklepovic +10 more

A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3817

N/A

0.477DataRank · unranked

23 citations

Rachel S. Heise, Kristen Ganjoo, Elizabeth J. Davis, Suzanne George, Melissa Burgess +16 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0.396DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Cancers(2022)10.3390/cancers14174334

N/A

0.269DataRank · unranked

5 citations

Cassandra Hennessy, Alicia Beeghly, Benjamin French, Dimpy P. Shah, Sarah Croessmann +42 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0.208DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11523

Top 71%

0.140DataRank

Top 71%1 citations

Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah +15 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0.104DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

A prospective study evaluating the association of patient-reported outcomes with activity level and sleep patterns in sarcoma survivors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.12085

Top 100%

0DataRank

Top 100%0 citations

Emma Schremp, Tatsuki Koyama, Lili Sun, Lauren King, Vicki L. Keedy +7 more

Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11548

N/A

0DataRank · unranked

0 citations

Michael H. Robinson, Lauren A. King, Emma Schremp, Adam X. Miranda, Juan M. Colazo +7 more

Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis

Expert Review of Anticancer Therapy(2025)10.1080/14737140.2025.2545551

N/A

0DataRank · unranked

1 citations

Rodney Dixon Dorand, Sean Cohen, Vicki L. Keedy, Scott C. Borinstein, Scott M. Schuetze +3 more

Outcomes after progression of disease with anti–PD‐1/PD‐L1 therapy for patients with advanced melanoma

Cancer(2020)10.1002/cncr.32984

N/A

0DataRank · unranked

40 citations

Laura X. Baker, Elizabeth J. Davis, Haocan Song, Fei Ye, Douglas B. Johnson +1 more

Trends in the design of FDA registrational randomised clinical trials in haematology and oncology: a 20-year cohort study

BMJ Connections Oncology(2025)10.1136/bmjconc-2025-000063

N/A

0DataRank · unranked

0 citations

Агеносов Михаил Петрович, Wayne H. Liang, Elizabeth J. Davis, Carolyn Petersen, Talal Hilal +4 more

A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance

Cancer Cell(2020)10.1016/j.ccell.2020.10.022

N/A

0DataRank · unranked

33 citations

David M. Aboulafia, Melissa Accordino, Jared D. Acoba, Manmeet S. Ahluwalia, Syed A. Ahmad +95 more

Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma

JAMA Oncology(2021)10.1001/jamaoncol.2021.0051

N/A

0DataRank · unranked

254 citations

Rebecca Johnson, Aleigha Lawless, Prachi Bhave, Amelia Sawyers, Maya Dimitrova +15 more

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11503

N/A

0DataRank · unranked

10 citations

Karla V. Ballman, Kristen Ganjoo, Elizabeth J. Davis, Jeffrey A. Morgan, Gabriel Tinoco +15 more

A pilot study of the feasibility and utility of a fitness tracker to correlate activity level with patient reported outcomes (PROs) in sarcoma patients undergoing systemic therapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11559

N/A

0DataRank · unranked

0 citations

Gregory D. Ayers, Deborah Wallace, Elizabeth Kaiser, Vicki L. Keedy, Rajiv Agarwal +1 more

Efficacy of liposomal doxorubicin in patients with intra- and extra-abdominal desmoid fibromatosis.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11581

N/A

0DataRank · unranked

3 citations

Sean Cohen, Vicki L. Keedy, Scott C. Borinstein, Rashmi Chugh, Elizabeth J. Davis +1 more

A multicenter evaluation of treatment patterns and outcomes for Adamantinoma-like Ewing sarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e23500

N/A

0DataRank · unranked

1 citations

Daniel Ying Wang, Vicki L. Keedy, Elizabeth J. Davis, Rodney Dixon Dorand

A Retrospective Multi-Institutional Cohort Analysis of Clinical Characteristics and Outcomes in Dedifferentiated Chondrosarcoma

Cancers(2023)10.3390/cancers15092617

N/A

0DataRank · unranked

17 citations

Hilary Dietz, Sheima Farag, Angela C. Hirbe, Michael J. Wagner, Brian A. Van Tine +5 more

Elizabeth J. Davis

Indexed papers

Top data-sharing exemplar

Papers